- Home
- MAIA vs OTLK Comparison
MAIA vs OTLK Comparison
Compare MAIA & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAIA
- OTLK
- Stock Information
- Founded
- MAIA 2018
- OTLK 2010
- Country
- MAIA United States
- OTLK United States
- Employees
- MAIA N/A
- OTLK N/A
- Industry
- MAIA Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MAIA Health Care
- OTLK Health Care
- Exchange
- MAIA Nasdaq
- OTLK Nasdaq
- Market Cap
- MAIA 46.7M
- OTLK 48.3M
- IPO Year
- MAIA 2022
- OTLK 2016
- Fundamental
- Price
- MAIA $1.74
- OTLK $1.75
- Analyst Decision
- MAIA
- OTLK Strong Buy
- Analyst Count
- MAIA 0
- OTLK 5
- Target Price
- MAIA N/A
- OTLK $9.60
- AVG Volume (30 Days)
- MAIA 417.6K
- OTLK 786.0K
- Earning Date
- MAIA 08-08-2025
- OTLK 08-13-2025
- Dividend Yield
- MAIA N/A
- OTLK N/A
- EPS Growth
- MAIA N/A
- OTLK N/A
- EPS
- MAIA N/A
- OTLK 0.83
- Revenue
- MAIA N/A
- OTLK N/A
- Revenue This Year
- MAIA N/A
- OTLK N/A
- Revenue Next Year
- MAIA N/A
- OTLK $379.84
- P/E Ratio
- MAIA N/A
- OTLK $2.11
- Revenue Growth
- MAIA N/A
- OTLK N/A
- 52 Week Low
- MAIA $1.40
- OTLK $0.87
- 52 Week High
- MAIA $4.24
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- MAIA 47.75
- OTLK 50.96
- Support Level
- MAIA $1.66
- OTLK $1.65
- Resistance Level
- MAIA $1.95
- OTLK $2.04
- Average True Range (ATR)
- MAIA 0.12
- OTLK 0.12
- MACD
- MAIA -0.00
- OTLK -0.02
- Stochastic Oscillator
- MAIA 31.82
- OTLK 25.64
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.